Hepatitis C virus infection and rituximab therapy after renal transplantation

Fabrizi Fabrizio, Paul Martin, A. Elli, G. Montagnino, G. Banfi, P. Passerini, M. R. Campise, A. Tarantino, C. Ponticelli

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background. Rituximab, a chimeric monoclonal antibody, has been successfully given in various diseases including HCV-associated mixed cryoglobulinemia. However, only preliminary data exists on its efficacy and safety after renal transplantation. Methods. We report on a renal transplant recipient with chronic hepatitis C who received rituximab therapy for gastric cancer. Four rituximab infusions of 375 mg/m2 were given. Results. Rituximab therapy was complicated by cholestatic hepatitis C with very high HCV RNA levels; liver insufficiency occurred. The patient developed bacterial pneumoniae and respiratory insufficiency was the cause of death. Although other mechanisms cannot be excluded, we found that rituximab therapy was implicated in the pathogenesis of cholestatic hepatitis C in our patient. Conclusions. We suggest that rituximab therapy may be associated with significant side effects. More experience has to be accumulated before any conclusions on efficacy and safety of rituximab therapy after RT can be drawn.

Original languageEnglish
Pages (from-to)445-449
Number of pages5
JournalInternational Journal of Artificial Organs
Volume30
Issue number5
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Virus Diseases
Viruses
Hepacivirus
Kidney Transplantation
Transplantation (surgical)
Transplants
Monoclonal antibodies
RNA
Liver
Hepatitis C
Therapeutics
Hepatic Insufficiency
Safety
Bacterial Pneumonia
Cryoglobulinemia
Chronic Hepatitis C
Rituximab
Respiratory Insufficiency
Stomach Neoplasms
Cause of Death

Keywords

  • Gastric cancer
  • Hepatitis C
  • Renal transplant
  • Rituximab

ASJC Scopus subject areas

  • Biophysics

Cite this

Fabrizio, F., Martin, P., Elli, A., Montagnino, G., Banfi, G., Passerini, P., ... Ponticelli, C. (2007). Hepatitis C virus infection and rituximab therapy after renal transplantation. International Journal of Artificial Organs, 30(5), 445-449.

Hepatitis C virus infection and rituximab therapy after renal transplantation. / Fabrizio, Fabrizi; Martin, Paul; Elli, A.; Montagnino, G.; Banfi, G.; Passerini, P.; Campise, M. R.; Tarantino, A.; Ponticelli, C.

In: International Journal of Artificial Organs, Vol. 30, No. 5, 01.05.2007, p. 445-449.

Research output: Contribution to journalArticle

Fabrizio, F, Martin, P, Elli, A, Montagnino, G, Banfi, G, Passerini, P, Campise, MR, Tarantino, A & Ponticelli, C 2007, 'Hepatitis C virus infection and rituximab therapy after renal transplantation', International Journal of Artificial Organs, vol. 30, no. 5, pp. 445-449.
Fabrizio F, Martin P, Elli A, Montagnino G, Banfi G, Passerini P et al. Hepatitis C virus infection and rituximab therapy after renal transplantation. International Journal of Artificial Organs. 2007 May 1;30(5):445-449.
Fabrizio, Fabrizi ; Martin, Paul ; Elli, A. ; Montagnino, G. ; Banfi, G. ; Passerini, P. ; Campise, M. R. ; Tarantino, A. ; Ponticelli, C. / Hepatitis C virus infection and rituximab therapy after renal transplantation. In: International Journal of Artificial Organs. 2007 ; Vol. 30, No. 5. pp. 445-449.
@article{7274e4070b504ceab017e7af8209a2f3,
title = "Hepatitis C virus infection and rituximab therapy after renal transplantation",
abstract = "Background. Rituximab, a chimeric monoclonal antibody, has been successfully given in various diseases including HCV-associated mixed cryoglobulinemia. However, only preliminary data exists on its efficacy and safety after renal transplantation. Methods. We report on a renal transplant recipient with chronic hepatitis C who received rituximab therapy for gastric cancer. Four rituximab infusions of 375 mg/m2 were given. Results. Rituximab therapy was complicated by cholestatic hepatitis C with very high HCV RNA levels; liver insufficiency occurred. The patient developed bacterial pneumoniae and respiratory insufficiency was the cause of death. Although other mechanisms cannot be excluded, we found that rituximab therapy was implicated in the pathogenesis of cholestatic hepatitis C in our patient. Conclusions. We suggest that rituximab therapy may be associated with significant side effects. More experience has to be accumulated before any conclusions on efficacy and safety of rituximab therapy after RT can be drawn.",
keywords = "Gastric cancer, Hepatitis C, Renal transplant, Rituximab",
author = "Fabrizi Fabrizio and Paul Martin and A. Elli and G. Montagnino and G. Banfi and P. Passerini and Campise, {M. R.} and A. Tarantino and C. Ponticelli",
year = "2007",
month = "5",
day = "1",
language = "English",
volume = "30",
pages = "445--449",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "5",

}

TY - JOUR

T1 - Hepatitis C virus infection and rituximab therapy after renal transplantation

AU - Fabrizio, Fabrizi

AU - Martin, Paul

AU - Elli, A.

AU - Montagnino, G.

AU - Banfi, G.

AU - Passerini, P.

AU - Campise, M. R.

AU - Tarantino, A.

AU - Ponticelli, C.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Background. Rituximab, a chimeric monoclonal antibody, has been successfully given in various diseases including HCV-associated mixed cryoglobulinemia. However, only preliminary data exists on its efficacy and safety after renal transplantation. Methods. We report on a renal transplant recipient with chronic hepatitis C who received rituximab therapy for gastric cancer. Four rituximab infusions of 375 mg/m2 were given. Results. Rituximab therapy was complicated by cholestatic hepatitis C with very high HCV RNA levels; liver insufficiency occurred. The patient developed bacterial pneumoniae and respiratory insufficiency was the cause of death. Although other mechanisms cannot be excluded, we found that rituximab therapy was implicated in the pathogenesis of cholestatic hepatitis C in our patient. Conclusions. We suggest that rituximab therapy may be associated with significant side effects. More experience has to be accumulated before any conclusions on efficacy and safety of rituximab therapy after RT can be drawn.

AB - Background. Rituximab, a chimeric monoclonal antibody, has been successfully given in various diseases including HCV-associated mixed cryoglobulinemia. However, only preliminary data exists on its efficacy and safety after renal transplantation. Methods. We report on a renal transplant recipient with chronic hepatitis C who received rituximab therapy for gastric cancer. Four rituximab infusions of 375 mg/m2 were given. Results. Rituximab therapy was complicated by cholestatic hepatitis C with very high HCV RNA levels; liver insufficiency occurred. The patient developed bacterial pneumoniae and respiratory insufficiency was the cause of death. Although other mechanisms cannot be excluded, we found that rituximab therapy was implicated in the pathogenesis of cholestatic hepatitis C in our patient. Conclusions. We suggest that rituximab therapy may be associated with significant side effects. More experience has to be accumulated before any conclusions on efficacy and safety of rituximab therapy after RT can be drawn.

KW - Gastric cancer

KW - Hepatitis C

KW - Renal transplant

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=34447509807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447509807&partnerID=8YFLogxK

M3 - Article

C2 - 17551909

AN - SCOPUS:34447509807

VL - 30

SP - 445

EP - 449

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 5

ER -